Loading
Extracellular Vesicles in Disease / RNA Interference and Gene Delivery / CRISPR and Genetic Engineering · Journal article
Scripta Score Scientific Medical Journal · August 28, 2026
Raises a question worth testing. It does not answer one.
This literature review synthesizes published evidence on the theoretical potential of CRISPR-Cas9 delivered via extracellular vesicles as a strategy to target HIV at multiple lifecycle stages and eliminate latent reservoirs. The review presents mechanistic rationale and preclinical findings but explicitly concludes that human safety, efficacy, and clinical applicability remain unevaluated and require further study.
Literature review. Conceptual review; no human population studied. Discussion relates to potential application in HIV-infected individuals.. Intervention: CRISPR-Cas9 conjugated with extracellular vesicle delivery systems.
CRISPR-Cas9 can target multiple stages of the HIV life cycle including disruption of viral entry coreceptors, inhibition of viral replication, and elimination of latent proviral DNA Extracellular vesicles offer advantages as delivery vehicles including high biocompatibility, low immunogenicity, and efficient intracellular delivery of CRISPR-Cas9 components Several studies have demonstrated that CRISPR-Cas9 combined with extracellular vesicle delivery can reduce HIV proviral expression and prevent reactivation of latent viral reservoirs
Authors explicitly state that safety and clinical applicability in humans remain unevaluated.
This review does not provide clinical evidence to guide practice. It outlines a conceptual therapeutic approach that requires substantial further preclinical and clinical validation before any patient application can be considered.
This is a literature review synthesizing preclinical and mechanistic evidence about CRISPR-Cas9 delivery via extracellular vesicles for HIV; no original data, clinical trials, or human efficacy evidence is presented, and the authors explicitly state further studies are needed before clinical applicability can be evaluated.
As stated by the source record.
This review does not provide clinical evidence to guide practice. It outlines a conceptual therapeutic approach that requires substantial further preclinical and clinical validation before any patient application can be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background: Human Immunodeficiency Virus (HIV) remains a major global health challenge with high morbidity and mortality rates. Although antiretroviral therapy (ART) effectively suppresses viral replication, it is unable to eradicate latent HIV reservoirs, preventing complete viral clearance. Advances in genome editing technologies, particularly Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR-Cas9), have created new opportunities for HIV treatment through the targeted elimination of integrated viral genetic material. Objective: This study aimed to review the potential of CRISPR-Cas9 conjugated with extracellular vesicle delivery systems as a therapeutic strategy for HIV based on current scientific evidence. Methods: A literature review was conducted using scientific articles retrieved from PubMed, ScienceDirect, NCBI, and other relevant scientific databases. Relevant studies were critically reviewed and synthesized to evaluate its therapeutic potential for HIV treatment. Discussion: The findings indicate that CRISPR-Cas9 can target multiple stages of the HIV life cycle, including disruption of viral entry coreceptors, inhibition of viral replication, and elimination of latent proviral DNA integrated within host genomes. Furthermore, extracellular vesicles offer several advantages as delivery vehicles, including high biocompatibility, low immunogenicity, and efficient intracellular delivery of CRISPR-Cas9 components. Several studies have demonstrated that the combination of CRISPR-Cas9 and extracellular vesicle-based delivery systems can reduce HIV proviral expression and prevent the reactivation of latent viral reservoirs. Conclusion: CRISPR-Cas9 conjugated with extracellular vesicle delivery systems represents a promising therapeutic approach for HIV treatment. However, further studies are required to evaluate its safety, efficacy, and clinical applicability in humans. Keywords: CRISPR-Cas9, extracellular vesicles, gene therapy, genome editing, HIV. Latar Belakang: Human Immunodeficiency Virus (HIV) masih menjadi tantangan kesehatan global dengan angka morbiditas dan mortalitas yang tinggi. Meskipun terapi antiretroviral (ART) efektif dalam menekan replikasi virus, terapi ini belum mampu mengeliminasi reservoir laten HIV sehingga belum dapat memberikan kesembuhan secara menyeluruh. Perkembangan teknologi genome editing, khususnya Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR-Cas9), membuka peluang baru dalam terapi HIV melalui eliminasi materi genetik virus yang terintegrasi pada genom inang. Tujuan: Mengkaji potensi CRISPR-Cas9 yang dihantarkan menggunakan vesikel ekstraseluler sebagai strategi terapeutik HIV berdasarkan bukti ilmiah terkini. Metode: Penelitian ini menggunakan metode literature review dengan menelaah berbagai artikel ilmiah yang diperoleh dari PubMed, ScienceDirect, NCBI, dan sumber ilmiah relevan lainnya. Artikel yang relevan ditelaah secara kritis dan disintesis untuk mengevaluasi potensi terapeutik pendekatan tersebut dalam pengobatan HIV. Pembahasan: Kajian menunjukkan bahwa CRISPR-Cas9 mampu menargetkan berbagai tahap siklus hidup HIV, termasuk menghambat koreseptor masuknya virus, mengganggu replikasi virus, serta mengeliminasi provirus laten yang terintegrasi dalam genom sel inang. Selain itu, vesikel ekstraseluler memiliki keunggulan sebagai sistem penghantar karena bersifat biokompatibel, memiliki imunogenisitas rendah, serta mampu meningkatkan efisiensi pengiriman komponen CRISPR-Cas9 ke sel target. Beberapa penelitian menunjukkan bahwa kombinasi CRISPR-Cas9 dan vesikel ekstraseluler mampu menurunkan ekspresi provirus HIV dan menghambat aktivasi ulang reservoir laten. Kesimpulan: CRISPR-Cas9 yang dihantarkan menggunakan vesikel ekstraseluler berpotensi menjadi strategi terapeutik inovatif untuk HIV. Meskipun demikian, penelitian lebih lanjut masih diperlukan untuk mengevaluasi keamanan, efikasi, dan aplikasinya pada manusia. Keyword: CRISPR-Cas9, HIV, penyuntingan genom, terapi gen, vesikel ekstraseluler.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.